Ciphergen to Present Data at IGCS Supporting Use of Protein Biomarkers to Improve Detection of Ovarian Cancer
October 13 2006 - 10:00AM
PR Newswire (US)
FREMONT, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) today announced multiple
presentations with its collaborators supporting the use of protein
biomarkers to help discriminate women with ovarian cancer from
those with benign tumors and to help predict survival in patients
with ovarian cancer. The presentations will be made at the
International Gynecologic Cancer Society (IGCS) Biennial Meeting in
Santa Monica, Calif., October 14-18. "A diagnostic test is needed
that has adequate predictive value to stratify patients with a
pelvic mass into high risk of ovarian cancer from those with low
risk," said Eric T. Fung, M.D., Ph.D., Chief Scientific Officer for
Ciphergen Biosystems. "As published in the Journal of the National
Cancer Institutes in February, studies have shown that women with
ovarian cancer have better outcomes when triaged to a gynecologic
oncologist for treatment. The presentations at IGCS are further
evidence supporting the development of Ciphergen's panel of
biomarkers to help differentiate women with ovarian cancer and
thereby aid in insuring that they receive the most appropriate
medical attention." Each abstract will be presented on Sunday,
October 15, 2006 from 12:30-1:30 p.m. during Poster Session 1:
Ovarian in the Exhibition Area. Abstract: A Panel of Seven
Biomarkers Improves Detection of Ovarian Cancer Collaborators: John
Hopkins Medical Institutions, Nara Medical University Abstract: A
Panel of Seven Biomarkers Improves Specificity in Discriminating
Malignant from Benign Pelvic Masses Collaborators: The Danish
Cancer Society, John Hopkins Medical Institutions, University of
Copenhagen Abstract: Validation of a Panel of Seven Proteomic
Biomarkers in an Independent and Blinded Sample Set Collaborators:
John Hopkins Medical Institutions, Lund University Hospital
Abstract: Novel Biomarkers that Predict Survival in Patients with
Ovarian Cancer Collaborator: University of Copenhagen Abstract:
Evaluation of Pre-Analytic Influence of Sample Collection/Handling
Methodologies on Serum Proteome is Key in Biomarker Discovery and
Assay Development Collaborators: University College London, Royal
Holloway College About Ciphergen's Ovarian Cancer Diagnostic
Program Ciphergen has an advanced diagnostic program in ovarian
cancer and has developed a panel of biomarkers that provides risk
stratification information for ovarian cancer based on a series of
studies involving over 2,000 clinical samples from more than five
sites. Ciphergen has an alliance with Quest Diagnostics to
commercialize this marker set under the analyte specific reagent,
or ASR, regulations. Ciphergen is simultaneously undertaking a
prospective clinical trial to support submission to the FDA for
approval as an in vitro diagnostic test. In addition to developing
a diagnostic test designed to distinguish between benign and
malignant pelvic masses, studies are underway to predict recurrence
of ovarian cancer and to provide additional tools to aid physicians
in triaging women considered at high risk of ovarian cancer.
Ciphergen's comprehensive diagnostic development program is being
conducted with several leading collaborators at The Johns Hopkins
School of Medicine, The University of Texas M.D. Anderson Cancer
Center, University College London, and the University of Kentucky.
About Ovarian Cancer Commonly known as the "silent killer," ovarian
cancer leads to approximately 14,000 deaths each year in the United
States. Approximately 23,000 new cases are diagnosed each year,
with the majority in patients diagnosed with late stage disease
where the cancer has spread beyond the ovary. The prognosis is poor
in these patients, leading to the high mortality from this disease.
A diagnostic test is needed that can provide adequate predictive
value to stratify patients with a pelvic mass into high risk of
invasive ovarian cancer versus those with low risk. About Ciphergen
Ciphergen Biosystems, Inc. is dedicated to the discovery,
development and commercialization of novel high-value diagnostic
tests that help physicians diagnose, treat and improve outcomes for
patients. Ciphergen, along with its prestigious scientific
collaborators, has ongoing diagnostic programs in oncology,
cardiology and women's health with an initial focus in ovarian
cancer. Based in Fremont, California, more information about
Ciphergen can be found on the Web at http://www.ciphergen.com/ .
Safe Harbor Statement Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements. For
purposes of the Private Securities Litigation Reform Act of 1995
(the "Act"), Ciphergen disclaims any intent or obligation to update
these forward-looking statements, and claims the protection of the
Safe Harbor for forward-looking statements contained in the Act.
Examples of such forward-looking statements include statements
regarding the predictive value and usefulness of the protein
biomarker panel described in this publication in helping
discriminate women with ovarian cancer from women with benign
ovarian tumors or other benign disease, in predicting survival in
patients with ovarian cancer and in helping stratify patients with
a pelvic mass into high risk of ovarian cancer from those with low
risk of ovarian cancer, the ability of Ciphergen to commercialize
successfully such biomarker panel under the analyte specific
reagent (ASR) regulations and the potential outcome of studies
designed to predict recurrence of ovarian cancer and to provide
additional tools to aid physicians in triaging women considered at
high risk of ovarian cancer. Actual results may differ materially
from those projected in such forward-looking statements due to
various factors, including the possibility that the biomarker panel
described in this publication may not validate in subsequent
studies or be developed into an assay that is useful to physicians
and patients, the risk that such biomarker panel may not predict
successfully the recurrence of ovarian cancer or provide additional
tools to aid physicians in triaging women considered at high risk
of ovarian cancer, and the Company's ability to successfully
commercialize such tests. Investors should consult Ciphergen's
filings with the Securities and Exchange Commission, including its
Form 10-Q filed August 16, 2006, for further information regarding
these and other risks related to the Company's business. NOTE:
Ciphergen, ProteinChip and Biomarker Discovery Center are
registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE:
Ciphergen Biosystems, Inc. CONTACT: investors, Sue Carruthers of
Ciphergen Biosystems, Inc., +1-510-505 2233; or media, Andrea
Campbell of WeissComm Partners, +1-281-360-7239, for Ciphergen
Biosystems, Inc. Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024